Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has shared an update.
Hangzhou Tigermed Consulting Co., Ltd. has announced that its board of directors will convene on October 28, 2025, to discuss and approve the company’s third quarterly report for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s positioning in the consulting industry.
The most recent analyst rating on (HK:3347) stock is a Buy with a HK$62.10 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a joint stock company incorporated in China, operating in the consulting industry. The company focuses on providing a range of consulting services, although specific market focus or primary products are not detailed in the announcement.
Average Trading Volume: 3,464,941
Technical Sentiment Signal: Buy
Current Market Cap: HK$46.75B
See more data about 3347 stock on TipRanks’ Stock Analysis page.